Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2003

View Archived Issues

Phase I interim safety data reported for Reolysin in malignant glioma

Results reported for NBI-3001 in glioblastoma

Cytogen regains rights to ex vivo prostate cancer immunotherapy

Velcade enters phase II trial in colorectal cancer

MoliChem reacquires rights to Moli-1901

AEterna acquires Zentaris from Degussa

Zindaclin receives further E.U. approvals

NexMed completes dosing in two-year rat carcinogenicity study

Crucell regains rights to anti-CD46 antibody

IND filed for EOS-200-4

Topamax sNDA submitted for migraine prevention

Xenova advances two new programs into preclinical research

Restasis receives FDA approval

Amylin to acquire rights to Restoragen's GLP-1 program

Inspra meets primary endpoints in EPHESUS trial

COX-2-specific inhibitor LAS-34475 compares favorably to naproxen in osteoarthritis

HDAC inhibitor MS-275 active against pediatric solid tumors in vitro and in vivo

Third phase III MorphiDex trial fails to meet endpoints

Pharmacokinetic, toxicity and efficacy data for LEraf-AON in animals

Highly selective CB2 receptor ligand emerges from SAR studies at U.S. universities

New central muscle relaxant/antiinflammatory/analgesic advanced to clinical evaluation at GSK

Novel caspase inhibitors and their use reported by Vertex

Anticonvulsant compounds in early development at UCB

Ono patent covers new endothelial differentiation gene-1 (EDG1) agonists

New JAK3 inhibitors identified at AstraZeneca

Nonredox antiobesity cobalt porphyrin complexes discovered at MitoKor

Modified antisense oligonucleotides targeting ICAM-1 and VCAM-1 show potential in IBD

Galderma describes new series of vitamin D analogues for skin disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.